Recursion Pharmaceuticals dropped for a third straight day on Wednesday, slashing 6.29 percent to close at $4.77 apiece after investors mimicked the recent selling of three company executives.

Explore RXRX's upcoming H2'25 trial updates for REC-4881 in familial adenomatous polyposis and REC-617.

According to data compiled by S&P Global Market Intelligence, Recursion Pharmaceuticals (NASDAQ: RXRX) stock was shedding more than 17% of its value week-to-date as of Thursday night.

No: Kierkegaard was referring to anxiety itself. He believed that understanding and using one’s anxiety was the great ...

This article presents analytical, Monte Carlo, and empirical evidence on combining recursive and rolling forecasts when linear predictive models are subject to structural change. Using a ...

Summary The Defender’s Log episode features John Todd from Quad9, discussing their mission to protect the internet through secure DNS. Quad9, a non-profit launched in 2017 with founding partners ...

During Operation Sindoor, the IAF carried out a long-range strike from around 300 kilometres, downing what it suspects was an ELINT or AEW&C aircraft – both regarded as high-value command and ...

Governments are racing to build AI smarter than humans. Experts warn the first to reach AGI could reshape global ...

Three writers discuss Trump’s deployment of the National Guard to combat crime in the capital city.

What is redistricting? Your questions about maps, California’s feud with Texas and more, answered The latest feud between President Donald Trump and Gov. Gavin Newsom could affect who you're ...